A. Krishnan

发表

Dietary n‐3 Fatty Acids Decrease Osteoclastogenesis and Loss of Bone Mass in Ovariectomized Mice

Dongxu Sun, G. Fernandes, A. Bhattacharya, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of Dietary n-3 and n-6 Oils with and without Food Restriction on Activity of Antioxidant Enzymes and Lipid Peroxidation in Livers of Cyclophosphamide Treated Autoimmune-Prone NZB/W Female Mice

Dongxu Sun, G. Fernandes, A. Bhattacharya, 2003, Journal of the American College of Nutrition.

Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts

Jessica M. Rusert, J. Mesirov, R. Wechsler-Reya, 2022, Journal of proteome research.

Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice.

Dongxu Sun, G. Fernandes, R. Lawrence, 2004, Cellular immunology.

Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease.

A. Limaye, J. Longmate, D. Diamond, 2008, The Journal of infectious diseases.

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

W. Britt, D. Diamond, Zhongde Wang, 2007, Vaccine.

Chimeric Vastus Lateralis and Anterolateral Thigh Flap for Restoring Facial Defects and Dynamic Function following Radical Parotidectomy.

Jonathan R. Clark, S. Ch’ng, B. Ashford, 2019, Plastic and reconstructive surgery.

Predicting Kinase-Substrate Interactions in Medulloblastoma Subtypes

Jessica M. Rusert, Aparna Krishnan, Patrick Pirrotte, 2020, 2020 IEEE 20th International Conference on Bioinformatics and Bioengineering (BIBE).

Free Vibration Studies of Woodpecker Inspired Layered Shock Absorbing Structure

A. Ramesh, B. Biju, A. Krishnan, 2019 .

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.

A. Limaye, J. Longmate, D. Diamond, 2007, The Journal of infectious diseases.

Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients

A. Limaye, J. Longmate, D. Diamond, 2011, Transplant international : official journal of the European Society for Organ Transplantation.

A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.

D. Diamond, Zhongde Wang, P. Manchanda, 2008, Immunology letters.

Predictors of electroconvulsive therapy postictal delirium.

M. Hayat, I. Reti, K. Neufeld, 2014, Psychosomatics.

Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.

A. Limaye, J. Zaia, Lia Thao, 2006, The Journal of infectious diseases.

TrypZean™: An Animal-Free Alternative to Bovine Trypsin

S. Woodard, A. Krishnan, 2014 .

from a granule protease in CML patients and HLA-A2 transgenic mice Characterization of immunologic properties of a second HLA-A2 epitope

H. Andersson, S. Forman, L. Cooper, 2012 .

Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.

H. Andersson, S. Forman, L. Cooper, 2011, Blood.

In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.

J. Longmate, D. Diamond, S. Lacey, 2006, Experimental hematology.

Programmed death‐1 receptor and interleukin‐10 in liver transplant recipients at high risk for late cytomegalovirus disease

D. Diamond, S. Lacey, A. Limaye, 2010, Transplant infectious disease : an official journal of the Transplantation Society.

Tacrolimus and Sirolimus as GVHD Prophylaxis for Sibling Donor Hematopoietic Stem Cell Transplant (HCT) Using Three Conditioning Regimens; Fludarabine-Melphalan, FTBI-VP16, and Busulfan-Cyclophosphamide

S. Forman, D. Senitzer, D. Snyder, 2009 .

Can people-centered community-oriented interventions improve skilled birth attendance? Evidence from a quasi-experimental study in rural communities of Cambodia, Kenya, and Zambia

A. Edward, H. Perry, A. Ghee, 2019, BMC Pregnancy and Childbirth.

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

K. Anderson, A. Krishnan, S. Lonial, 2007 .

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Zhezhen Jin, P. Richardson, E. Guinan, 2004 .

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial.

Zhezhen Jin, P. Richardson, E. Guinan, 2006 .

Should HIV-positive patients with lymphoma be offered stem cell transplants?

A. Krishnan, J. Zaia, S. Forman, 2003, Bone Marrow Transplantation.

Hematologic Aspects of HIV/AIDS.

D. Scadden, J. Zaia, A. Levine, 2001, Hematology. American Society of Hematology. Education Program.

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

K. Anderson, A. Jakubowiak, A. Krishnan, 2007 .

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM).

S. Lonial, P. Richardson, C. Mitsiades, 2005, Journal of Clinical Oncology.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.

H. Andersson, S. Forman, L. Cooper, 2011, Blood.